Caffeine citrate for very preterm infants: Effects on development, temperament and behaviour

Journal of Paediatrics and Child Health

Volumn 47, Issue 4, 2011, Pages 167-172

  Gray, Peter H ^a,b   Flenady, Vicki J ^a   Charles, Bruce G ^a   Steer, Peter A ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER MOTHERS HOSPITAL   (Australia)

^c Children's Health Services District   (Australia)

Author keywords

behaviour; caffeine; development; preterm; temperament

Indexed keywords

AMINOPHYLLINE; CAFFEINE CITRATE; LUNG SURFACTANT; METHYLXANTHINE; STEROID;

ARTICLE; ARTIFICIAL VENTILATION; BIRTH WEIGHT; CHILD; CHILD BEHAVIOR; COGNITIVE DEVELOPMENT; CONTROLLED STUDY; DISABILITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; EXTUBATION; GESTATIONAL AGE; HUMAN; INFANT; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE PREGNANCY; NEUROLOGIC EXAMINATION; NEWBORN APNEA; NEWBORN DEATH; NEWBORN MORBIDITY; OUTCOME ASSESSMENT; PERINATAL DEVELOPMENT; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY DISTRESS SYNDROME; SIDE EFFECT; SURVIVOR; TEMPERAMENT;

AUSTRALIA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD DEVELOPMENT; CITRATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT BEHAVIOR; INFANT MORTALITY; INFANT, NEWBORN; MALE; PREMATURE BIRTH; QUESTIONNAIRES; TEMPERAMENT;

EID: 79955158242     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2010.01943.x     Document Type: Article

References (26)

1. Theobald K, Botwinski C, Albanna S, McWilliam P,. Apnea of prematurity: diagnosis, implications for care and pharmacologic management. Neonatal Netw. 2000; 19: 17-24.
2. Steer P, Flenady V, Shearman A, et al,. High dose caffeine for extubation of preterm infants: A randomised controlled trial. Arch. Dis. Child. Fetal Neonatal Ed. 2004; 89: F499-503. (Pubitemid 39472318)
3. Millar D, Schmidt B,. Controversies surrounding xanthine therapy. Semin. Neonatol. 2004; 9: 239-44. (Pubitemid 38525028)
4. Bauer J, Maier K, Linderkamp O, Hentschel R,. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics 2001; 107: 660-3. (Pubitemid 32268448)
5. 2A knockout mice. Stroke 2003; 34: 739-44. (Pubitemid 36307404)
6. Chen JF, Huang Z, Ma J, et al,. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischaemia in mice. J. Neurosci. 1999; 19: 9192-200. (Pubitemid 30228071)
7. Schmidt B, Roberts RS, Davis P, et al,., for the Caffeine for Apnea of Prematurity Group. Long-term effects of caffeine therapy for apnea of prematurity. N. Engl. J. Med. 2007; 357: 1893-902. (Pubitemid 350074685)
8. 2a receptor. Nature 1997; 388: 674-8. (Pubitemid 27366438)
9. 1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur. J. Neurosci. 2002; 16: 547-50. (Pubitemid 35471874)
10. Pan HZ, Chen HH,. Hyperalgesia, low-anxiety, and impairment of avoidance learning in neonatal caffeine-treated rats. Psychopharmacology 2007; 191: 119-25.
11. Comer AM, Perry CM, Figgit DP,. Caffeine citrate: A review of its use in apnoea of prematurity. Pediatr. Drugs 2001; 3: 61-79. (Pubitemid 32115680)
12. Schmidt B, Roberts RS, Davis P, et al,. Caffeine for apnea of prematurity. N. Engl. J. Med. 2006; 354: 2112-21.
13. Scanlon JEM, Chin KC, Morgan MEI, Durbin GM, Hale KA, Brown SS,. Caffeine or theophylline for neonatal apnoea. Arch. Dis. Child. 1992; 67: 425-8.
14. Steer PA, Flenady VJ, Shearman A, Lee TC, Tudehope DI, Charles BG,. Periextubation caffeine in preterm neonates: A randomised dose-response trial. J. Paediatr. Child Health 2003; 39: 511-5. (Pubitemid 37267068)
15. Mutch L, Alberman E, Hagberg B, Koduma K, Perat MV,. Cerebral palsy epidemiology: where are we now and where are we going. Dev. Med. Child Neurol. 1992; 34: 547-55.
16. Griffiths R,. The Griffiths Mental Developmental Scales. Henley on Thames, UK: Association for Research in Infant and Child Development, 1996.
17. Sanson A, Prior M, Garino E, Oberklaid F, Sewell J,. The structure of infant temperament: factor analysis of the Revised Infant Temperament Questionnaire. Infant Behav. Dev. 1987; 10: 97-104.
18. Pedlow R, Sanson A, Prior M, Oberklaid F,. Stability of maternally reported temperament from infancy to 8 years. Dev. Psychol. 1993; 6: 998-1007.
19. Richman N, Stevenson J, Graham PJ,. Pre-School to School. London: Academic Press, 1982.
20. Gray PH, Burns YR, Mohay HA, O'Callaghan MJ, Tudehope DI,. Neurodevelopmental outcome of preterm infants with bronchopulmonary dysplasia. Arch. Dis. Child. 1995; 73: F128-34.
21. Jeng SF, Hsu CH, Tsao PN, et al,. Bronchopulmonary dysplasia predicts adverse developmental and clinical outcomes in very-low-birthweight infants. Dev. Med. Child Neurol. 2008; 50: 51-7.
22. Janvier A, Khairy M, Athanasios A, Cormier C, Messmer D, Barrington KJ,. Apnea is associated with neurodevelopmental impairment in very low birth weight infants. J. Perinatol. 2004; 24: 763-8. (Pubitemid 39618583)
23. Goldsmith HH, Buss AH, Plomin R, et al,. Roundtable: what is temperament? Four approaches. Child Dev. 1987; 58: 505-29.
24. Prior M, Sanson A, Smart D, Oberklaid F,. Pathways from Infancy to Adolescence: Australian Temperament Project 1983-2000. Melbourne, Australia: Australian Institute of Family Studies, 2000.
25. Prior MR, Sanson AV, Oberklaid F,. The Australian temperament project. In:, Kohnstamm GA, Bates JE, Rothbart MK, eds. Temperament in Childhood. Chichester, England, UK: John Wiley & Sons Ltd., 2007; 537-54.
26. Schmidt B, for the CAP 5-Year Steering Committee. Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the International Caffeine for Apnea of Prematurity (CAP) trial. Biol. Neonate 2005; 88: 208-13. (Pubitemid 41433553)